• EE402 The Monte Carlo Model as a Tool for Estimating the Economic Burden of Ectopic Pregnancy by Predicting Future Cases

    Dec 1, 2024, 00:00

  • HSD89 Changes in Pneumococcal and Hexavalent Vaccination Schedule in Term-Born Infants: Potential Impact on Preterm Infants

    Dec 1, 2024, 00:00

  • EE312 Artificial Intelligence Prediction Tool for Prediabetes and Type 2 Diabetes Risk Stratification Using Computed Tomography Scans: An Early Economic Evaluation

    Dec 1, 2024, 00:00

  • HSD103 Scoping Review on Attitudes and Barriers Towards Therapeutic Drug Monitoring for Biological Treatments for Immune-Mediated Inflammatory Diseases Among Key Stakeholders

    Dec 1, 2024, 00:00

  • HPR57 How Did the Urban and Rural Resident Basic Medical Insurance Integration Affect Medical Costs? Evidence From China

    Dec 1, 2024, 00:00

  • EE347 Cost-Effectiveness and Value-Based Price of High-Dose Quadrivalent Influenza Vaccine Among Elderly Populations in Taiwan

    Dec 1, 2024, 00:00

  • EE556 Long-Term Outcomes in Hemophilia: The Impact of the Pettersson Score on Cost-Effectiveness Modelling

    Dec 1, 2024, 00:00

  • EE253 Health Care Visits and Out-of-Pocket Costs in People With Chronic Hand Eczema

    Dec 1, 2024, 00:00

  • HPR15 Innovative Rebate Management in Oncology Drug Budgets: Streamlining Operations and Enhancing Financial Efficiency Through Technology in Newfoundland and Labrador's Cancer Care Program

    Dec 1, 2024, 00:00

  • EPH261 Incidence and Prevalence of Non-Idiopathic Pulmonary Fibrosis (IPF) Progressive Fibrosing Interstitial Lung Disease (PF-ILD): A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • HSD63 Use of Resources and Cost in the Management of Gastrointestinal Bleeding Associated With Direct Oral Anticoagulants or Warfarin

    Dec 1, 2024, 00:00

  • EPH92 The Last of Fungus? Recent Developments in Fungal Infections in the German Hospital Setting

    Dec 1, 2024, 00:00

  • HTA4 Literature Review of Methods for Evaluating and Selecting Medical Devices at Hospital Level

    Dec 1, 2024, 00:00

  • HTA129 Potential Impact of Joint Clinical Assessment (JCA) on Health Technology Assessment Timelines in Ireland

    Dec 1, 2024, 00:00

  • HPR64 Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD124 Application of Diagnosis-Related Group (DRG) in Measuring the Impact of Clinical Pathway on Resource Utilization for Patients Suspected With Acute Coronary Syndrome in the Emergency Department

    Dec 1, 2024, 00:00

  • CO132 Evaluating the Effectiveness of Switching Treatments in Chronic Psoriasis: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • HTA141 Artificial Intelligen Is It a New Era in Payer Decision Making?

    Dec 1, 2024, 00:00

  • HPR233 Impacts of National Volume-Based Procurement Policy on Prices of Non-Winning Drugs in China: An Interrupted Time Series

    Dec 1, 2024, 00:00

  • EE797 Health Care Resource Use Associated With Respiratory Syncytial Virus Infection in Infants and Young Children in Germany: Evidence From the PAPI Study

    Dec 1, 2024, 00:00

  • EE781 Budget Impact Analysis of Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis in Algeria

    Dec 1, 2024, 00:00

  • HPR31 Payer Preferences Around Manufacturer Provided Evidence and Engagements in the US

    Dec 1, 2024, 00:00

  • P8 Assessment of CO2 Equivalent Emissions in Effective Type 2 Diabetes Management: An Economic Modelling Study

    Dec 1, 2024, 00:00

  • EPH220 Payer-Reported Patient Burden for Hematopoietic Cell Transplantation (HCT) in the United States

    Dec 1, 2024, 00:00

  • EPH282 3-Year Healthcare Resource Consumptions of Patients With Immunoglobulin A Nephropathy in a Large Real-World Italian Database

    Dec 1, 2024, 00:00

  • HPR137 Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis

    Dec 1, 2024, 00:00

  • HSD18 Exploration of the Perception on Physical Activity and Its Correlation With Patients' Quality of Life at Vironas Health Center

    Dec 1, 2024, 00:00

  • EE417 Quantifying the Value of Aztreonam-Avibactam in Treating Suspected Metallo-Beta-Lactamase Producing Enterobacterales Infections in Gree A STEDI Value Approach

    Dec 1, 2024, 00:00

  • EPH152 An Age-Period-Cohort Approach to Studying Long-Term Trends in Obesity and Overweight in Women in Ghana (2003–2023)

    Dec 1, 2024, 00:00

  • EE803 Systematic Review of Healthcare Costs and Resource Utilization in Fibromyalgia in European Countries and the US

    Dec 1, 2024, 00:00

  • EE687 Cost-Effectiveness of Advanced Therapies Initiation in Patients With Rheumatoid Arthritis (RA) in Spain, Who Failed a Conventional Synthetic DMARD Versus a First Biological DMARD

    Dec 1, 2024, 00:00

  • CO71 HTA Assessment of Quality of Survival Via Patient-Relevant Endpoints in Prostate Cancer

    Dec 1, 2024, 00:00

  • PT33 Cost-Effectiveness of Adjuvant Radiation Therapy Versus Tamoxifen Alone in Older Adult Women With Early-Stage Breast Cancer

    Dec 1, 2024, 00:00

  • EE440 Cost-Effectiveness of Bioabsorbable Nasal Implant (Latera®) Versus Conservative Management for the Treatment of Nasal Airway Obstruction (NAO)

    Dec 1, 2024, 00:00

  • HSD35 Effectiveness of a Combined Approach of Home-Based Respiratory Rehabilitation and Tele-Rehabilitation for Patients With Chronic Obstructive Pulmonary Disease (COPD)

    Dec 1, 2024, 00:00

  • HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map

    Dec 1, 2024, 00:00

  • HSD17 Job Satisfaction Quality of Life of Greek Employees Working in Mental Health Rehabilitation Units in Greece

    Dec 1, 2024, 00:00

  • EPH237 Vedolizumab Induced Cachexia: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2024, 00:00

  • HTA174 A Call for Standardization: Navigating the Inconsistency in European HTA Pharmacoeconomic Guideline Reporting

    Dec 1, 2024, 00:00

  • EE672 Optimizing Costs and Sustainability for Gamma Knife Radiosurgery: A Cost and Breakeven Analysis at India's Largest Neurosurgery Centre

    Dec 1, 2024, 00:00

  • CO12 Predictors of Treatment and Recovery Among Obese Patients in the United States: A Retrospective Observational Study Using the PINC AI Healthcare Database (PHD)

    Dec 1, 2024, 00:00

  • HPR247 Analysis of Oncology Medicine Distribution in Türkiye: A Focus on Indication, Molecule, and Generic Status

    Dec 1, 2024, 00:00

  • EPH289 Effect of Anti-Rheumatic Drugs on Diabetic Foot Disease Among Patients With Type 2 Diabetes and Rheumatoid Arthritis

    Dec 1, 2024, 00:00

  • HTA215 Targeted Review: Generalizability of Clinical Trial Evidence to the Patient Population in NICE Technology Appraisals

    Dec 1, 2024, 00:00

  • EE333 Cost-Effectiveness Analysis on New Generation Heat and Moisture Exchangers for Laryngectomized Patients in Japan

    Dec 1, 2024, 00:00

  • EE433 Cost Effectiveness (CE) Evidence Overview for Metformin and SGLT2is in Type 2 Diabetes (T2D) Patients With Cardiorenal Risk: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EE431 The Economic Burden of Advanced/Metastatic Biliary Tract Cancer: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • HTA46 Difficulties of Choosing Proper Endpoints in Anti-Obesity Therapy Assessment

    Dec 1, 2024, 00:00

  • EE385 Economic Burden of Hepatocellular Carcinoma (HCC) Treated With a Curative Resection or Ablation (R/A) in Fran Liverpool Study

    Dec 1, 2024, 00:00

  • EPH203 Impact of Gender-Based Violence Cases in Bolívar, Colombia 2023

    Dec 1, 2024, 00:00

  • EPH50 Current Trends in the Application of Fecal Microbiota Transfer (FMT) in German Hospitals

    Dec 1, 2024, 00:00

  • EE608 Assessing the Economic Burden of Rare Disease Across Europe: A Health Economic Study of Financial and Quality of Life Impacts

    Dec 1, 2024, 00:00

  • EE296 A Nonactive Implant for the Treatment of Chronic Gastro-Oesophageal Reflux Disease: Cost-Effectiveness Analysis From an Italian Healthcare Payer Perspective

    Dec 1, 2024, 00:00

  • EE453 Clinical and Economic Benefits of Adopting Cladribine Tablets for the Treatment of Relapsing: Remitting Multiple Sclerosis in Public Health Service Institutions in Mexico

    Dec 1, 2024, 00:00

  • EPH155 The Impact of Adjuvant Alectinib in Reducing Recurrences and Recurrence-Related Treatment Costs in Resected Early-Stage ALK+ Non-Small Cell Lung Cancer Across Canada

    Dec 1, 2024, 00:00

  • HSD10 Reimbursement of Remote Health Services in Turkiye

    Dec 1, 2024, 00:00

  • EE555 A New Approach to One-Way Sensitivity Analysis and the Tornado Plot

    Dec 1, 2024, 00:00

  • HPR235 The Impact of Dispensing and Non-Dispensing Practices on Outpatient Service Utilization and Expenses Under the Dual-Channel Policy in China

    Dec 1, 2024, 00:00

  • HSD48 The Impact of Medication Reconciliation on Discrepancies and All-Cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-Experimental Study

    Dec 1, 2024, 00:00

  • EE328 The Cost-Effectiveness of Germline BRCA Testing in Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

    Dec 1, 2024, 00:00

  • HSD125 Patient Pathways and Healthcare Resources Use in Hepatocellular Carcinoma: Full Analyses of the OPAL Study in Portuguese Population

    Dec 1, 2024, 00:00

  • CO5 Healthcare Resource Utilization and Costs of Endometrial Cancer in France From 2016 to 2021 (MOONBEAM Study)

    Dec 1, 2024, 00:00

  • EPH247 How Is Climate Change Affecting the Spread of Vector-, Water-, and Food-Borne Diseases?

    Dec 1, 2024, 00:00

  • EPH267 Estimating the Health Economic Benefits of Physical Activity for People With Limited Mobility

    Dec 1, 2024, 00:00

  • EE266 Cost-Effectiveness of Newborn Screening for Congenital Adrenal Hyperplasia in Japan

    Dec 1, 2024, 00:00

  • EE336 Real-World US Optum Claims Database Study of Pre- and Post-Relapse Costs and Health Care Resource Utilization (HCRU) in Patients With High-Risk Localized or Locally Advanced Prostate Cancer (HR-LPC/LAPC) Who Relapsed

    Dec 1, 2024, 00:00

  • HPR129 An Umbrella Review of the Impacts of Climate Change on Maternal Health and Birth Outcomes

    Dec 1, 2024, 00:00

  • EE564 Cost-Effectiveness of Alirocumab in Combination With High-Intensity Statin and Ezetimibe in Adults With Atherosclerotic Cardiovascular Disease (ASCVD) in Taiwan

    Dec 1, 2024, 00:00

  • EE675 Behavioral Considerations in Stated Preference Valuation of Human Life Metrics: Cost Vector Effects, Anchoring and Scope-Insensitivity

    Dec 1, 2024, 00:00

  • HSD1 The Growth of Online Consultations in China: A 10-Year Sequential Cross-Sectional Study of 65,305 Clinicians

    Dec 1, 2024, 00:00

  • EE628 Systemic Therapy of Atopic Dermatitis in Germany: Real-World Data on Care Structures and Economic Implications in a Retrospective Longitudinal Study

    Dec 1, 2024, 00:00

  • HTA224 A Roadmap to the Use of Value of Information Analysis in Health Technology Assessment: An International Study of Barriers, Facilitators, and Potential Applications

    Dec 1, 2024, 00:00

  • EE454 Budget Impact Analysis of Bimekizumab for the Treatment of Axial Spondyloarthritis (axSpA) in Greece

    Dec 1, 2024, 00:00

  • HSD14 Understanding Physicians Decision Making Processes When Treating Mild -to-Moderate Chronic Kidney Disease: A Qualitative Study

    Dec 1, 2024, 00:00

  • EE375 An Early Health Economic Assessment on a New Method to Estimate 12-Hour Lithium Levels

    Dec 1, 2024, 00:00

  • EPH200 Administrative Frequency of Migraine and Clinical Characteristics in a Colombian Cohort From 2018 to 2022

    Dec 1, 2024, 00:00

  • EE372 Direct Health Care Costs Associated With Myasthenia Gravis (MG) in Hungary: A Claims Database Analysis

    Dec 1, 2024, 00:00

  • CO92 Comparative Efficacy and Safety of Faricimab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion (RVO): A Systematic Literature Review and Network Meta-Analysis

    Dec 1, 2024, 00:00

  • PT23 The Evolving German DiGA Market: Insights From a Claims Data Analysis

    Dec 1, 2024, 00:00

  • EE764 Cost Analysis of Rechargeable vs Non-Rechargeable Devices for Deep Brain Stimulation in Parkinson's Disease Treatment in Spain

    Dec 1, 2024, 00:00

  • P9 Recommended Standards for Managing and Reporting Missing Utility Data for Health Technology Appraisal

    Dec 1, 2024, 00:00

  • EE320 Cost-Effectiveness of Glofitamab vs Chemoimmunotherapy Regimens for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RRDLBCL) After at Least Two Lines of Systemic Therapy in the Czech Republic

    Dec 1, 2024, 00:00

  • HPR118 The Relationship Between Income Per Capita and Meningococcal Serogroup B Vaccination Rates in Gree An Ecological Correlation Analysis

    Dec 1, 2024, 00:00

  • HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE566 Real-World Evidence of Multi-Gene Panel Sequencing Effectiveness and Cost-Effectiveness for Advanced Cancers: A Tumor-Agnostic Target Trial Emulation

    Dec 1, 2024, 00:00

  • EE300 Public Health Impact of Nirsevimab for RSV Prophylaxis in Infants: Insights From the Paraguayan Healthcare System

    Dec 1, 2024, 00:00

  • EE813 When Does It Make Sense to Increase the Use of Thromboprophylaxis? An Analysis in Ten Countries

    Dec 1, 2024, 00:00

  • HTA181 Stakeholder Engagement in HTA: A Matter for Consensus?

    Dec 1, 2024, 00:00

  • EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands

    Dec 1, 2024, 00:00

  • CO21 Acupuncture for Spasticity After Stroke: A Systematic Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EPH250 HPV Vaccination Deficit AMONG Girls in Gree Where We Are Now?

    Dec 1, 2024, 00:00

  • EE799 COVID-19 Vaccination of Individuals Aged 65 Years and Over in Fran Clinical and Economic Impact of Vaccine Choice

    Dec 1, 2024, 00:00

  • EE364 Cost-Effectiveness Analysis of Difelikefalin for the Treatment of Chronic Kidney Disease Associated-Pruritus in Spain

    Dec 1, 2024, 00:00

  • CO61 Discordance Between Apolipoprotein B and LDL-Cholesterol and Incident Hypertension Risk: An Analysis of US Real-World Data

    Dec 1, 2024, 00:00

  • HPR232 Eurocover-CLL: Reimbursement and Accessibility for New Treatments in Relapsed/Refractory Chronic Lymphocytic Leukemia in Central and Eastern Europe

    Dec 1, 2024, 00:00

  • HSD106 Influence of Initial Imaging Type on Time-to-Diagnosis Among Cancers Without Routine Screening Programs: A Seer-Medicare Study

    Dec 1, 2024, 00:00

  • EE664 Cost-Effectiveness Analysis of IDP-126, a Topical Triple Therapy, for the Treatment of Acne Vulgaris From the Perspective of Canadian Public Payers

    Dec 1, 2024, 00:00

  • EE352 Cost-Effectiveness of Chikungunya Vaccination With IXCHIQ in Adults in Puerto Rico

    Dec 1, 2024, 00:00

  • Cost-Effectiveness of an Extended-Role General Practitioner Clinic for Persistent Physical Symptoms: Results From the Multiple Symptoms Study 3 Pragmatic Randomized Controlled Trial

    Dec 1, 2024, 00:00

  • HPR106 Resource Allocation and Outcomes in the Greek Health System: Convergence and Divergence Within the Mediterranean Healthcare Model

    Dec 1, 2024, 00:00

  • HTA191 Main Restrictions Imposed by the National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC) for the Incorporation of Medications in Brazil

    Dec 1, 2024, 00:00

  • HSD135 Oncologists’ Perceptions of Nivolumab Plus Ipilumumab (NIVO + IPI) As First-Line (1L) Treatment for Microsatellite Instability-High/Mismatch Repair-Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)

    Dec 1, 2024, 00:00

  • HPR109 Unveiling the Fiscal Burden of Migraine in Argentina

    Dec 1, 2024, 00:00

  • EPH48 Impact of Influenza-like Illness on Health-Related Quality of Life in Japanese Adults

    Dec 1, 2024, 00:00

  • HPR148 Adopting CeSHarP M11 Guidelines for Oncology Protocol Digitalization: Findings and Action Recommendations

    Dec 1, 2024, 00:00

  • HSD52 Reducing Complications in Patients Living With Type 2 Diabetes by an Optimized Management of Weight and Glycemia and Their Associated Savings

    Dec 1, 2024, 00:00

  • HSD99 Evaluating the Efficiency of an Automated Pathway for Obstructive Sleep Apnoea Therapy Through a Digitally Enabled Workflow: An Observational Research Study

    Dec 1, 2024, 00:00

  • EE319 Economic Evaluation of Dynamic Coronary Roadmap (DCR) in Percutaneous Coronary Intervention (PCI)

    Dec 1, 2024, 00:00

  • EE796 Cost Effectiveness of Selexipag Versus Placebo for Patients With Pulmonary Arterial Hypertension in Singapore

    Dec 1, 2024, 00:00

  • HTA139 Disparities in New Drug Recommendations: A Comparative Analysis Between NICE and the SMC

    Dec 1, 2024, 00:00

  • EPH44 Evaluating the COVID-19 Responses of Belgium, Denmark, Germany, the Netherlands, Sweden and the United Kingdom, February-June 2020: A Counterfactual Modelling Study

    Dec 1, 2024, 00:00

  • HPR190 Targeted Screening Interventions for Breast Cancer: Impact on Economic and Health Outcomes in Disadvantaged Populations

    Dec 1, 2024, 00:00

  • HPR2 Addressing Legislative and Financial Hurdles in Rare Disease Medicines Accessibility: Insight From Czechia With a Focus on the Pediatric Population

    Dec 1, 2024, 00:00

  • EE668 Assessing the Impact of a Virtual Maternity Care Program on Total Cost of Care in a US Medicaid-Insured Population

    Dec 1, 2024, 00:00

  • EE269 Cost-Effectiveness Analysis of Fenofibrate for the Prevention of Diabetes Complications in People Suffering From Type 2 Diabetes Mellitus

    Dec 1, 2024, 00:00

  • EE357 Estimating Health State Utilities in LGMD 2E/R4, 2D/R3, and 2C/R5: Analysis of EQ-5D Baseline Data From the JOURNEY Natural History Study

    Dec 1, 2024, 00:00

  • EPH168 A Descriptive Epidemiological Study of Pediatric Sleep Medications in Japan: A Health Insurance Claims-Based Analysis

    Dec 1, 2024, 00:00

  • HPR198 Evaluation of the Early Access Program Evolution: A Three-Year Retrospective Analysis

    Dec 1, 2024, 00:00

  • HPR164 Antibiotic Consumption and an Opportunity for Savings by Pricing Regulation

    Dec 1, 2024, 00:00

  • CO51 Second-Line Pharmacological Interventions for Advanced Non-Small Cell Lung Cancer in MetEX14 Skipping Patients: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE399 Economic Analysis of Digital Health Infrastructure: The Case of OneLondon's Impact on Time Efficiency and Safety in Healthcare Services

    Dec 1, 2024, 00:00

  • EPH194 Estimating the Prevalence of Controversial Denials of Essential Medicines and Health Services Through Legal Case Review

    Dec 1, 2024, 00:00

  • P10 Responsiveness of Key Quality-of-Life Measures to Important Changes in the Lives of People With MS: The EQ-5D-3L and Multiple Sclerosis Impact Scale Eight Dimensions

    Dec 1, 2024, 00:00

  • EE833 Economic Burden of Atherosclerotic Cardiovascular Disease in France in 2021: Results From the French Nationwide Claims Database (SNDS)

    Dec 1, 2024, 00:00

  • EE397 Differential Health-Economic Outcomes of Anti-Amyloid Treatment for Alzheimer's Disease Between Ethnoracial Groups in the United States

    Dec 1, 2024, 00:00

  • EE511 Impact of Delayed Treatment Initiation With Resmetirom in Patients With Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) With Moderate to Advanced Fibrosis

    Dec 1, 2024, 00:00

  • EE369 Unintended Pregnancies in Türkiye: An in-Depth Analysis of Economic Burden

    Dec 1, 2024, 00:00

  • EE353 Cost-Consequence Analysis of Fremanezumab Treatment in Patients With Migraine and Comorbid Major Depressive Disorder in the UK Using Results From the UNITE Study

    Dec 1, 2024, 00:00

  • EE708 Assessment of Direct Costs of Human Papillomavirus Related Diseases in Saudi Arabia

    Dec 1, 2024, 00:00

  • EPH172 Unmet Needs and Spatiotemporal Variation in Vitiligo: A Retrospective Longitudinal Web Search Analysis

    Dec 1, 2024, 00:00

  • HTA121 Improving Literature Review Efficiency: Evaluating the Impact of the Opensource Asreview Tool on Time and Effort to Conduct Systematic and Targeted Reviews

    Dec 1, 2024, 00:00

  • EE470 Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Stroke Prevention in Atrial Fibrillation

    Dec 1, 2024, 00:00

  • HSD126 Evaluating the Degree of Coordination in Hypertension Medications Across Primary Healthcare Institutions, Secondary Hospitals, and Tertiary Hospitals in Shanghai, China

    Dec 1, 2024, 00:00

  • EE773 Impact of Improved Adherence to Insulin Injection Technique Recommendations on Health Care Expenditures in Insulin-Treated People With Diabetes in Belgium

    Dec 1, 2024, 00:00

  • EE638 Long COVID: A Costly Condition Imposing Substantial Burden on Society

    Dec 1, 2024, 00:00

  • HSD123 Precision Medicine Decision-Making in Metastatic Non-Small Cell Lung Cancer at Portuguese Hospitals

    Dec 1, 2024, 00:00

  • HTA33 Are Companies Ready for the New EU HTA, or Is It an Impossible Task?

    Dec 1, 2024, 00:00

  • HPR215 Exploring the Efficacy, Safety, and Regulatory Approval of Priority Reviewed Innovative Drugs in China (2015-2023)

    Dec 1, 2024, 00:00

  • EE818 Direct Medical Costs of Duchenne Muscular Dystrophy Patients: A Retrospective Observational Study Using Swedish Population-Based Register Data

    Dec 1, 2024, 00:00

  • EPH187 Contextualizing the Impact of Multiple Sclerosis (MS) in England Through HES Analysis

    Dec 1, 2024, 00:00

  • CO40 Efficacy and Safety of Difelikefalin in Patients Receiving Concomitant Opioid Medication

    Dec 1, 2024, 00:00

  • HPR218 The Impact of the Clinical Added Value Labels on Price Negotiation Duration

    Dec 1, 2024, 00:00

  • EE392 Public Health and Economic Impact of Gender-Neutral Nine-Valent Human Papillomavirus Vaccination Program in Algeria

    Dec 1, 2024, 00:00

  • EE635 Cost of Hypoglycemia in Individuals With Diabetes on the London Ambulance Servi A Study Using Real-World Data

    Dec 1, 2024, 00:00

  • EPH202 Investigation of the Factors Affecting Adherence to Antihypertensive Treatment in Hypertensive Patients With Newly Diagnosed Coronary Artery Disease

    Dec 1, 2024, 00:00

  • HSD101 Minimizing the Impact of Cardiovascular Disease: The Importance of Financial Incentives in Driving Secondary Prevention

    Dec 1, 2024, 00:00

  • HPR1 Evaluating High-Cost Innovative Medicines: A Three-Year Analysis of Pricing Trends in France's Early Access Programme (AAP)

    Dec 1, 2024, 00:00

  • EE689 Anti-PLA2R Antibody Testing for the Diagnosis of Primary Membranous Nephropathy: An Early Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • HPR179 Headache Patients’ Perspective on Access to Specialized Medical Care and Preventive Treatment in Portugal: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • HPR174 Authorization and Financing Situation in Spain of the New Medicines and Indications Authorized by the European Commission in the Period 2021-2023

    Dec 1, 2024, 00:00

  • EPH21 Incidence of Lichen Sclerosus in Men: A Systematic Review

    Dec 1, 2024, 00:00

  • CO108 Systematic Literature Review and Meta-Analysis of the Real-World Effectiveness and Safety of Avelumab in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

    Dec 1, 2024, 00:00

  • EPH170 Burden of Severe ANCA Associated Vasculitis in Australia via Real-World Usage of Rituximab

    Dec 1, 2024, 00:00

  • EPH35 The Phollow Cohort: Characteristics of Cannabis Prescription Based Medicines Users in Portugal

    Dec 1, 2024, 00:00

  • HPR175 Finding a Way for Patients to Access Gene Therapies

    Dec 1, 2024, 00:00

  • EPH140 Targeted Literature Review of the Clinical, Social, and Economic Burdens of Schizophrenia in Japan

    Dec 1, 2024, 00:00

  • EE516 Non-QALY Benefits of Treatments of Alzheimer's Disease and Related Dementias

    Dec 1, 2024, 00:00

  • HTA152 A Value Framework Based on Multiple Criteria Decision Analysis for New Health Technologies Assessment Under Universal Healthcare Coverage System in Taiwan

    Dec 1, 2024, 00:00

  • EPH281 Characteristics, Treatment Patterns, and Survival of Patients With Locally Advanced or Metastatic Renal Cell Carcinoma in England: Results of a Nationwide Cohort Study

    Dec 1, 2024, 00:00

  • HPR24 Use of Real-World Evidence to Support Regulatory Clearance of a Labeling Revision for Robotic-Assisted Radical Prostatectomy in the United States

    Dec 1, 2024, 00:00

  • EPH83 Public Health Impact of a Simplified Booster Vaccine Schedule Against Tick-Borne Encephalitis (TBE) in Austria: A Modeling Analysis

    Dec 1, 2024, 00:00

  • EE603 Cost-Effectiveness Analysis of Fecal Microbiota Transplantation in Recurrent or Refractory Clostridioides Difficile Infection in Taiwan

    Dec 1, 2024, 00:00

  • HTA93 Mixture Cure Models: A New Paradigm to Model Long-Term Remission (LTR) for Chimeric Antigen Receptor (CAR) T-Cell Therapies?

    Dec 1, 2024, 00:00

  • HTA66 The Safety and Effectiveness of Transurethral Water Vapor Ablation of Prostate: Literature Review

    Dec 1, 2024, 00:00

  • EE517 Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer

    Dec 1, 2024, 00:00

  • HSD42 Uptake of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction (HFrEF) and Disparities in the United States: A Medicare Database Study

    Dec 1, 2024, 00:00

  • HPR191 Utilization of a Managed Access Protocol to Enable Reimbursement of Liraglutide (Saxenda®) for Weight Management for Patients in Ireland

    Dec 1, 2024, 00:00

  • EE749 Socioeconomic Disparities in Hypertension Medication Adherence in Quezon City: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • HTA151 Rapid Review of Published Economic Evaluations of Larotrectinib and Entrectinib: Current Practices to Overcome Challenges in Health Technology Assessment of Tumor-Agnostic Treatments

    Dec 1, 2024, 00:00

  • EE381 Budget Impact of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia

    Dec 1, 2024, 00:00

  • HTA186 Oxford Digital Biomarkers for Dementia (OxDBD): Lean Assessment Process Methodology for Evaluating Clinical Needs, Adoption Barriers, and As Precursor for Early Economic Evaluation and Adoption Strategy in Acute NHS Hospitals

    Dec 1, 2024, 00:00

  • HTA14 Systematic Literature Reviews of Health-State Utility Values, Costs, and Healthcare Resource Use in Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2024, 00:00

  • HSD93 The Diagnosis and Management of Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review of Eight Countries Clinical Practice Guidelines

    Dec 1, 2024, 00:00

  • EE430 Evaluating the Cost Benefit of Fixed-Duration Targeted Therapy in First Line (1ST L) in Chronic Lymphocytic Leukemia (CLL ): A Real-World Analysis Using Hungarian Claims Data

    Dec 1, 2024, 00:00

  • CO85 Comparative Effectiveness of Fenfluramine and Cannabidiol for Dravet Syndrome: A Network Meta-Analysis

    Dec 1, 2024, 00:00

  • EPH5 The Burden of Severe Symptomatic Aortic Stenosis in Spain: Can Capacity-Enhancing Innovations Play a Role in Addressing the Growing Demand for Treatment?

    Dec 1, 2024, 00:00

  • HTA31 Insulin Analogs in Type 1 Diabetes Treatment: Is There Access After Unified Health System (SUS) Incorporation?

    Dec 1, 2024, 00:00

  • EE438 Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective

    Dec 1, 2024, 00:00

  • HTA218 Reimbursement Mechanisms Used by CAR-T Therapies in the EU5 (2018–2023)

    Dec 1, 2024, 00:00

  • EE619 Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Mortality in Type 2 Diabetes

    Dec 1, 2024, 00:00

  • EE591 Global Health Economic Burden of Angelman Syndrome: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • HTA196 Acceptance of Flexible Survival Models by the Swedish Dental and Pharmaceutical Benefits Agency (TLV) and the Norwegian Medical Products Agency (NOMA)

    Dec 1, 2024, 00:00

  • HSD51 The Impact of Medication Therapy Management Intervention on Patient-Reported Outcome (PRO) Measures in Patients With Myocardial Infarction (MI)

    Dec 1, 2024, 00:00

  • HPR71 Recommendations for Effective Patient Involvement in the Assessment of Medical Devices

    Dec 1, 2024, 00:00

  • EE529 Human Papilloma Virus in Italy: Cost of Illness and Potential Savings Due to HPV9 Primary Prevention in Adult Women

    Dec 1, 2024, 00:00

  • HTA85 Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?

    Dec 1, 2024, 00:00

  • HPR51 Analysis of the Risk Sharing System in Korea: From System Introduction to Present, Focusing on Types

    Dec 1, 2024, 00:00

  • CO95 HER2 Expression and Associated Real World Overall Survival (RWOS) in Patients With Select Solid Tumors

    Dec 1, 2024, 00:00

  • EE795 Healthcare Resource Utilization and Costs Associated With Infectious Mononucleosis in the United States

    Dec 1, 2024, 00:00

  • HTA219 Transporting Real-World Eviden Is It Possible to Transport OS Estimates in HER2+ mBC From US to UK?

    Dec 1, 2024, 00:00

  • EE594 Economic Burden of Triple-Negative Breast Cancer in Portugal

    Dec 1, 2024, 00:00

  • HPR88 Revolutionizing Market Access: AI-Driven Pricing Strategies in the Pharmaceutical Industry

    Dec 1, 2024, 00:00

  • HSD77 From Centralized Manufacturing to Bedside Production: Advancing CAR T-Cell Therapies Through Collaborative Innovation

    Dec 1, 2024, 00:00

  • EPH29 A Mixed Methods Study to Develop and Validate a National Patient Experience Survey (PES) to Support Service Delivery and Improvement

    Dec 1, 2024, 00:00

  • EE276 Budget Impact Analysis of RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Disease Among Older Adults in Argentina

    Dec 1, 2024, 00:00

  • HTA32 EU HTA Is Like a Box of Chocolates, You Never Know What You Are Going to Get: Necessity for EU PICO Simulations

    Dec 1, 2024, 00:00

  • EE583 Economic Burden of Dedifferentiated Liposarcoma in Metastatic and Non-Metastatic Patients: A Retrospective Observational Study Using Danish Population-Based Register Data

    Dec 1, 2024, 00:00

  • EPH132 Inadequate Response to Therapy Among Ulcerative Colitis Patients Initiating an Advanced Therapy: A Retrospective Analysis of German Health Claims Data

    Dec 1, 2024, 00:00

  • EE448 The Economic Impact of Polatuzumab Vedotin as First-Line Therapy for High-Risk DLBCL on Subsequent Treatments Within the Italian National Health Service

    Dec 1, 2024, 00:00

  • HTA1 Passing a Camel Through the Eye of a Needle: How Flexible Will the EU Joint Clinical Assessment Process Need to be to Fit the Time Available

    Dec 1, 2024, 00:00

  • EE486 Budget-Impact Model for the Use of Continuous Monitoring of Patient Vital Signs in US Hospital Medical-Surgical Floors

    Dec 1, 2024, 00:00

  • HTA115 Should We Change Our Approach to Conducting Indirect Treatment Comparisons for Joint Clinical Assessment? A Comparison With NICE Guidelines

    Dec 1, 2024, 00:00

  • HPR6 Early Access Programs in Northwest European Countries

    Dec 1, 2024, 00:00

  • EE348 Number Needed to Treat and Cost-per-Responder Analysis of Dupilumab and Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps

    Dec 1, 2024, 00:00

  • HSD70 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Australian Public Hospitals

    Dec 1, 2024, 00:00

  • EPH142 Incidence of Cardiovascular Disease Among Breast Cancer Patients by Age at Diagnosis: A Registry-Based Case-Control Study Using Real-World Evidence From Norway

    Dec 1, 2024, 00:00

  • EE538 Once-Weekly Icodec Versus Basal Insulin Analogs for the Treatment of Type 2 Diabetes in the UK: A Long-Term Cost-Effectiveness Analysis Based on a Post-Hoc Analysis of the Onwards 5 Clinical Trial

    Dec 1, 2024, 00:00

  • EE639 Cost-per-Responder Analysis of Bimekizumab Against Licensed Anti-Interleukin-17A Therapies in Axial Spondyloarthritis From a UK Perspective Focusing on BASDAI50 Treatment Response

    Dec 1, 2024, 00:00

  • EPH11 Burden of HPV-Associated Cancers in Mexico From 2011-2019

    Dec 1, 2024, 00:00

  • EE601 Using Dupilumab in Line With the England NICE Recommendation (TA534): Impact on the Healthcare Resource Utilization and Non-Medicine Cost

    Dec 1, 2024, 00:00

  • EE335 A Systematic Review of Health Economic Evaluations of Oral Nutritional Supplements as a Single-Component or Multi-Component Intervention in Older Adults With or at Risk of Malnutrition

    Dec 1, 2024, 00:00

  • HTA212 A Comparative Analysis of the QALY Shortfall and Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Methods As Ways to Account for Disease Severity in Cost-Effectiveness Analyses for Sickle Cell Disease

    Dec 1, 2024, 00:00

  • HPR202 Characterizing the Inequity of Major Diseases Among Adults in the City of Pécs, Hungary, 2024

    Dec 1, 2024, 00:00

  • EPH184 An Update on the Utilization and Expenditure Associated With Medicines for the Treatment of Diabetes, Over a 10-Year Period in Ireland

    Dec 1, 2024, 00:00

  • EPH129 Characteristics of Patients Prescribed Naldemedine in United Kingdom Primary Care: An Observational Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • HPR10 Assessing the Pricing Trends of Repurposed Medicines in the United Kingdom

    Dec 1, 2024, 00:00

  • HTA61 A Review of Health Technology Assessments Conducted for Tumor Agnostic Therapies Across the UK and EU4

    Dec 1, 2024, 00:00

  • HPR102 Antidiabetic Medicines Consumption and Cost for Payer and Patients During Pandemia: The Case for Bulgaria

    Dec 1, 2024, 00:00

  • HSD109 Home Health Care Utilization and Successful Aging Trajectories: Insights From the China Health and Retirement Longitudinal Study (CHARLS)

    Dec 1, 2024, 00:00

  • HPR58 Accessibility and Reimbursement Coverage of Rare Disease Drugs in China: Insights From the China's Lists of Rare Diseases

    Dec 1, 2024, 00:00

  • PT39 A Mixed-Methods Blueprint for Obesity Healthcare Policy: From Research to Action

    Dec 1, 2024, 00:00

  • EE768 Productivity Loss and Indirect Cost Related to Atopic Dermatitis in Greece

    Dec 1, 2024, 00:00

  • HPR169 Impact of Recent US Pricing Policy on the Price of Diabetes Drugs in the US

    Dec 1, 2024, 00:00

  • EPH111 Trends in Epidemiology and Mortality of Patients With Hyperlipidemia in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • P58 Consideration of Asylum Seekers, Refugees, and Recent Migrants When Evaluating Health Equity: Towards Leaving No One behind

    Dec 1, 2024, 00:00

  • EE396 Evaluating Long-Term Healthcare Resource Utilization in Biopsy-Confirmed MASLD: A Retrospective Longitudinal Observational Cohort Study in Sweden

    Dec 1, 2024, 00:00

  • HPR237 Price Determinants and Pricing Policies Concerning Potentially Innovative Health Technologies: A Scoping Review

    Dec 1, 2024, 00:00

  • CO2 Outcomes-Based Agreements and Real-World Data for Health Technology Reassessment of Orphan Drugs: Learnings from Belgium

    Dec 1, 2024, 00:00

  • P51 The State of the Art in Antimicrobial Resistance Economic Modelling: Is the STEDI Framework Being Used to Capture Value?

    Dec 1, 2024, 00:00

  • EE643 Assessing Healthcare Payer Perspective on Health Economic Model Transparency and Applicability to Own Setting

    Dec 1, 2024, 00:00

  • CO84 A Regression Discontinuity Model to Evaluate the Effect of Retirement on Phenotypic Aging: Results From a Large Cohort in China

    Dec 1, 2024, 00:00

  • CO32 Linguists’ Perceptions of Human- and Machine-Translated Clinical Outcome Assessment (COA) Wording: A Mixed Methods Study

    Dec 1, 2024, 00:00

  • EPH90 Burden of Disease of Primary Sclerosing Cholangitis: A Retrospective Cohort Study in Germany

    Dec 1, 2024, 00:00

  • EE283 Number of Needed to Treat (NNT) to Achieve Seizures Reduction or Seizure Freedom in Dravet Syndrome in Fran Results From an Itc of Stiripentol vs Fenfluramine and Cannabidiol and the Economic Implications

    Dec 1, 2024, 00:00

  • EE502 Prevalence, Cost, and Per-Patient Economic Burden of Hospital-Onset Bacteremia and Fungemia

    Dec 1, 2024, 00:00

  • EE774 Growth and Economic Trends of European CROs: Insights From the EUCROF Benchmarking Project

    Dec 1, 2024, 00:00

  • HPR125 Analysis of IPT Developed for the New Medicines and Indications Authorized by the European Commission During the 2021-2023 Period

    Dec 1, 2024, 00:00

  • EE605 Economic Evaluation of Lung Cancer Screening With Low-Dose Computed Tomography in Brazil

    Dec 1, 2024, 00:00

  • EPH143 Analysis of Italian Administrative Healthcare Data to Identify Rare Diseases and Describe Their Clinical Burden: The Case of Duchenne Muscular Distrophy

    Dec 1, 2024, 00:00

  • EE410 Budget Impact Analysis of NIPT Coverage in Korea: Focusing on Older Pregnant Women

    Dec 1, 2024, 00:00

  • EE542 Long-Term Extrapolation of Overall Survival (OS) and Progression-Free Survival (PFS) for the Lunar Trial in Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Progression on Platinum-Based Therapy

    Dec 1, 2024, 00:00

  • EE704 Cost-Effectiveness of a Community First Responder System for Out-of-Hospital Cardiac Arrest in Belgium

    Dec 1, 2024, 00:00

  • EE287 Cost-Effectiveness of Tirzepatide As an Adjunct to a Reduced-Calorie Diet and Increased Physical Activity Versus Diet and Exercise Alone in Patients With Obesity or Overweight From a UK Perspective

    Dec 1, 2024, 00:00

  • EE634 Impact of Patient's Financial Burden of COVID-19 Treatment on Antiviral Prescription Rates, and Clinical and Economic Outcomes in Japan

    Dec 1, 2024, 00:00

  • EPH182 A Temporal Network Analysis of Drug Co-Prescription Around Antidepressants and Anxiolytics Uses

    Dec 1, 2024, 00:00

  • HPR226 Unintended Consequences: The Inflation Reduction Act (IRA) and the Impact of the Small Manufacturer Discount Phase-in on Patient Access Over the Next Three Years (2025-2028)

    Dec 1, 2024, 00:00

  • EE841 Economic Evaluations of AI-Assisted Technology in Healthcare: How Are We Assessing the Cost-Effectiveness of These New Therapies?

    Dec 1, 2024, 00:00

  • EE432 Number Needed to Treat and Associated Costs/Additional Responder of Dupilumab Versus Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

    Dec 1, 2024, 00:00

  • EE589 Characterization and Treatment Patterns of Patients With Hypercholesterolemia Associated with Atherosclerotic Cardiovascular Disease and Risk Equivalent: Real-World Evidence in a Vulnerable Population in Colombia

    Dec 1, 2024, 00:00

  • CO4 The True Value of Living Systematic Reviews (LSRs): A Case Report Within Systemic Lupus Erythematosus (SLE)

    Dec 1, 2024, 00:00

  • EE251 Economic Evaluation and Budget Impact Analysis of a Novel Monotherapy for Advanced Melanoma With Low Pd-L1 Expression in Bulgaria

    Dec 1, 2024, 00:00

  • EE340 Ferric Derisomaltose Improves Quality of Life and Reduces Costs Relative to Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease and Iron Deficiency Anemia in Italy: Impact of Fractures

    Dec 1, 2024, 00:00

  • EE800 A Budget Impact Analysis of Reducing Viral Transmission With Baloxavir Marboxil Treatment for Seasonal Influenza in Japan

    Dec 1, 2024, 00:00

  • EPH45 Increased Access to Subcutaneous Relative to Intravenous Drug Regimens by Women and Minority Racial/Ethnic Patients Using Belimumab or Tocilizumab Among US Medicare Beneficiaries

    Dec 1, 2024, 00:00

  • EPH266 An Economic Model to Assess the Costs and Benefits of Workplace Mental Wellbeing Interventions: A Flexible Tool for Employers and Decision Makers

    Dec 1, 2024, 00:00

  • EE487 End of Life Resource Use of Real-World NSCLC Patients in Finland

    Dec 1, 2024, 00:00

  • HTA36 Robustness of Outcomes in Indirect Comparison Methods of Pegylated Liposomal Irinotecan for the Treatment of Metastatic Pancreatic Cancer in Patients Who Have Progressed Following Gemcitabine-Based Therapy

    Dec 1, 2024, 00:00

  • HTA221 Market Access Challenges for Gene Therapies in Inherited Blood Disorders: A Retrospective Evaluation of HTA Outcomes for Sickle Cell Disease and Thalassemia

    Dec 1, 2024, 00:00

  • EPH105 Prevalence of Metabolic and Micro-Vascular Complications Among English Adult Patients With Type 1 Diabetes Who Were Initiated on Basal Insulin Analogues Between 2014 and 2019: A Population-Based Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE332 Using Real-World Evidence to Estimate the Societal Burden of Obstructive Hypertrophic Cardiomyopathy in Norway: Productivity Losses From Absenteeism and Premature Death Based on Excess Mortality

    Dec 1, 2024, 00:00

  • Table of Contents

    Dec 1, 2024, 00:00

  • EE437 Cost-Effectiveness Analysis of a Non-Active Implant for Chronic Gastro-Oesophageal Reflux Disease in Spain

    Dec 1, 2024, 00:00

  • HSD81 Integrating IPU Principles for Improved Lung Cancer Care at an Oncology Center

    Dec 1, 2024, 00:00

  • EE574 Cost-Consequences Analysis of the Use of TyrxTM Antibacterial Envelope in Patients Undergoing Device Replacement Procedures in Türkiye

    Dec 1, 2024, 00:00

  • P2 Exploring the Unknown: Use of Sensitivity Analysis to Characterize Residual Uncertainty in Real-World External Control Arm Evidence Submitted to NICE

    Dec 1, 2024, 00:00

  • HTA73 Demonstrating the Value of Digital Solutions in Market Access

    Dec 1, 2024, 00:00

  • HTA79 A Framework for Early Health Technology Assessments of Screening Methods: A Case Study by Evaluating Fracture Risk in Community Dwelling Older Adults

    Dec 1, 2024, 00:00

  • HPR54 Managed Entry Agreements for Advanced Therapy Medicinal Products: Insights From Semi-Structured Interviews Across England, the Netherlands, and Spain

    Dec 1, 2024, 00:00

  • EE405 Cost-Effectiveness Analysis of Different Recombinant Factor VIII for Prophylactic Treatment of Previously Untreated Patients With Severe Hemophilia A in China

    Dec 1, 2024, 00:00

  • HSD114 A Pilot Project of Implementing P4P for Diabetes Management: Communication Strategy

    Dec 1, 2024, 00:00

  • EPH173 A Visual Representation of the Observational Study of Extended Adjuvant Neratinib in HER2+ Early Breast Cancer (EBC) in the Context of the European Early Access Program (EAP): Near Study Final Results

    Dec 1, 2024, 00:00

  • HSD23 Effectiveness of a Quality Improvement Collaboration With Community Nurses to Reduce Hospital Referrals Due to Tunnelled Haemodialysis Catheter Dysfunction

    Dec 1, 2024, 00:00

  • EE678 Health Economic Evaluation and Budget Impact Analysis of Population-Based Screening for Chronic Obstructive Pulmonary Disease (COPD) in China

    Dec 1, 2024, 00:00

  • EPH30 Assessing the Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345, With a Broad Vaccination Campaign Among Older Adults in the United Kingdom: Modelling Study

    Dec 1, 2024, 00:00

  • EPH16 New Onset Depression During Pregnancy in Commercially-Insured and Medicaid-Insured Pregnancies in the United States

    Dec 1, 2024, 00:00

  • HTA116 Navigating Market Access After Conditional Reimbursement: Principles for Disinvesting Orphan Drugs

    Dec 1, 2024, 00:00

  • CO89 Reductions in Concomitant Medication Use and HbA1c Impact Following Initiation of an Advanced Hybrid Closed-Loop System (AHCL) Versus Multiple Daily Injection (MDI) Therapy in People With Type 2 Diabetes (T2D)

    Dec 1, 2024, 00:00

  • EE461 The Preventable Cost of Diabetes in the United Kingdom

    Dec 1, 2024, 00:00

  • EE270 Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line

    Dec 1, 2024, 00:00

  • HSD92 The Evolution of Single-Use Ureteroscope Use in the United States

    Dec 1, 2024, 00:00

  • HTA157 Evidence Transfer in European Drug Approval and German Early Benefit Assessments: An Empirical Analysis

    Dec 1, 2024, 00:00

  • P1 Indirect Treatment Comparison of Larotrectinib vs Entrectinib in NTRK-Fusion Solid Tumors: Demonstration of a Novel Bayesian Hierarchical Modelling Approach for Basket Trials

    Dec 1, 2024, 00:00

  • HTA111 EU Joint Clinical Assessment (JCA): Uncertain Impact on German Amnog Timelines and Potential Delays

    Dec 1, 2024, 00:00

  • HPR104 Value Recognition of Combination Vaccines: What Is Needed to Support Access and Uptake?

    Dec 1, 2024, 00:00

  • A Causal Model for Primary Prevention of Cardiovascular Disease: The Health Economic Model for the Primary Prevention of Cardiovascular Disease [Editor's Choice]

    Dec 1, 2024, 00:00

  • HTA44 Unlocking Equitable Access to Revolutionary Cell and Gene Therapies Across EU Member States

    Dec 1, 2024, 00:00

  • HPR166 Understanding Differences in Pharmaceutical Products Based on Price Publication Status

    Dec 1, 2024, 00:00

  • EPH219 Desk-Sharing in Workplaces: Economic Analysis of Targeted Hygiene Intervention (THI) in Reducing Risk of Common Infections

    Dec 1, 2024, 00:00

  • CO10 Characterizing the Burden and Unmet Need of Membranous Nephropathy

    Dec 1, 2024, 00:00

  • EE362 Tirzepatide in the Treatment of Diabetes: A Systematic Overeview of Economic Evaluations

    Dec 1, 2024, 00:00

  • EE407 Budget Impact Analysis of Paliperidone Palmitate in Chronic Schizophrenia in the Mental Health Secretariat-Egyptian Ministry of Health

    Dec 1, 2024, 00:00

  • HTA83 Assessing Health Technology Assessment (HTA) Outcomes for Conditionally Approved Drugs by the European Medicines Agency (EMA) in Germany, France, and England

    Dec 1, 2024, 00:00

  • HPR163 Best Practices Identified From the Analysis of 8 European Countries’ National Cancer Plans

    Dec 1, 2024, 00:00

  • EE770 Clinical and Economic Burden Attributable to Serotypes in Current Pneumococcal Conjugate Vaccines in Turkey

    Dec 1, 2024, 00:00

  • EE313 Model-Based Assessment of the Costs and Benefits of Lung Cancer Screening in the Czech Republic Before Introduction of the National Pilot Program

    Dec 1, 2024, 00:00

  • EE831 Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Locally Advanced and Metastatic Urothelial Cancer in Fran A Non-Interventional Database Study

    Dec 1, 2024, 00:00

  • EE569 Finnish Society Gains 2.6 Billion Euros of Value Annually From the Pharmaceutical Work Provided by the Licensed Community Pharmacies

    Dec 1, 2024, 00:00

  • EE515 Cost-Effectiveness Analysis of Sacubitril/Valsartan in Heart Failure Patients in Egypt

    Dec 1, 2024, 00:00

  • EE317 What Are the Lessons Learned From the Assessments of Economic Evaluations of Orphan Drugs Submitted by Manufacturers to the French National Authority for Health (HAS) From 2014 to 2024?

    Dec 1, 2024, 00:00

  • EPH174 Medication Use Patterns Associated With Post-COVID-19 Condition: Results From a Longitudinal Cohort Study

    Dec 1, 2024, 00:00

  • The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs

    Dec 1, 2024, 00:00

  • EE667 An Economic Evaluation of Herpes Zoster Vaccination With the Recombinant Vaccine for Adults in Ireland

    Dec 1, 2024, 00:00

  • HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists

    Dec 1, 2024, 00:00

  • EE465 The Impact of Time-Dependent Events on Semi-Markov Models With Treatment Sequencing: A Simulation Study

    Dec 1, 2024, 00:00

  • EPH95 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer in Belgium

    Dec 1, 2024, 00:00

  • HTA2 Developing a System-Centric Framework for Health Technology Value Assessment

    Dec 1, 2024, 00:00

  • EPH212 Prevalence of Pulmonary Embolism Among Medicare Enrollees: A Six-Year Perspective

    Dec 1, 2024, 00:00

  • EE728 Cost-Effectiveness of the Use of Trailblazer Support Catheter in Endovascular Interventional Procedures of Peripheral Vascular Diseases in Turkey

    Dec 1, 2024, 00:00

  • HPR203 Navigating the EMA Qualification Process: Opportunities and Challenges for Accelerating Market Entry for Breakthrough Treatments and Vaccines

    Dec 1, 2024, 00:00

  • HSD115 Results and Implications of a Red Blood Cell (RBC) and Platelet Transfusion Costing Exercise in Select Countries within Europe and North America

    Dec 1, 2024, 00:00

  • EPH12 Hospitalization Rates of HPV-Associated Cancers in Brazil From 2011-2019

    Dec 1, 2024, 00:00

  • EE367 Health Care Resource Utilization and Costs Among Patients With Severe Hypertriglyceridemia and Acute Pancreatitis or Major Adverse Cardiovascular Events

    Dec 1, 2024, 00:00

  • HPR239 Alternative Ways of Financing Healthcare Systems: Investigating the Fiscal Impact of Health Taxes in Greece

    Dec 1, 2024, 00:00

  • HTA80 Health Technology Assessment of Robot-Assisted Versus Laparoscopic Low Anterior Resection for Middle and Low Rectal Cancer: A Prospective Cohort Study

    Dec 1, 2024, 00:00

  • HTA148 Off-Label Comparators in Health Technology Assessment Decision Making in Portugal

    Dec 1, 2024, 00:00

  • EPH283 Incidence and Severity of Acute Burns Treated in Austrian Hospitals and Degree of Cross States Care

    Dec 1, 2024, 00:00

  • EPH46 Urate Lowering Therapy in Patients With Subcutaneous Tophi

    Dec 1, 2024, 00:00

  • CO14 Glycaemic Control, Obesity Management, and Cardiovascular Outcomes of Semaglutide for Type 2 Diabetes Mellitus Patients: An Umbrella Review of Meta-Analyses of Randomized Clinical Trials

    Dec 1, 2024, 00:00

  • EPH33 Risk Factors for Psoriasis: An Umbrella Review of 12 Published Metanalyses

    Dec 1, 2024, 00:00

  • HPR41 Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe

    Dec 1, 2024, 00:00

  • EE519 Cost-Effectiveness Analysis of Osteosarcoma Treatment: Insights From a Systemic Literature Review

    Dec 1, 2024, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2024, 00:00

  • EE315 Building an Open-Source Semi-Markov State Transition Model for Use in Economic Evaluations of Early-Stage Cancer Treatments

    Dec 1, 2024, 00:00

  • EPH180 Understanding New Onset Type 1 Diabetes in Children Under 15 Years: An Overview From 4 Algerian Centers in 2023

    Dec 1, 2024, 00:00

  • EE422 Budget Impact of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (nAMD) in Ireland

    Dec 1, 2024, 00:00

  • EE565 Decision-Analytic Model-Based Economic Evaluations of Integrated Care Interventions for Cardiometabolic Multimorbidity: A Systematic Review

    Dec 1, 2024, 00:00

  • EE595 Cognitive Behavioral Therapy for Insomnia (CBT-I) Compared to Z-Drugs for the Treatment of Insomnia in the Elderly: A Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • HPR139 Health Technology Assessment Recommendations for Pharmaceutical Drugs Submitted in Blood Disorders in CDA and INESSS: Focus on Rare Diseases

    Dec 1, 2024, 00:00

  • HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe

    Dec 1, 2024, 00:00

  • CO117 Risk of Cardiovascular Events, Cancer, and All-Cause Mortality in JAK Inhibitors Compared to TNF Inhibitors: Analysis of a Large Real-World Claims Database

    Dec 1, 2024, 00:00

  • EE273 Understanding Costs and Health Utilities in Relation to Symptom Burden in a Large European Survey of Patients With Central Disorders of Hypersomnolence

    Dec 1, 2024, 00:00

  • EE586 Can Artificial Intelligence Be Used to Improve the Incremental Cost Effectiveness Ratio (ICER)? Modelling Utilities as Functions of Health States in Non Small Cell Lung Cancer

    Dec 1, 2024, 00:00

  • EE758 Landmark-Response Models: NICE in Theory, Not Submitted to NICE in Practice

    Dec 1, 2024, 00:00

  • CO76 The Effectiveness, Safety, and Cost-Reductions of an Intervention Bundle for Reducing Length of Stay in Laparoscopic Cholecystectomy Patients

    Dec 1, 2024, 00:00

  • HPR206 Evaluating the Maturity Level of Health Technology Assessment in Latin America: A Comparative Qualitative Analysis

    Dec 1, 2024, 00:00

  • EPH59 Developing and Validating Predictive Models of Vaccine Hesitancy Among Parents in the United States

    Dec 1, 2024, 00:00

  • PT34 Evaluating the Healthcare Burden and Clinical Impact of Polypharmacy Among the Elderly in South Korea

    Dec 1, 2024, 00:00

  • CO62 Allogeneic Stem Cell Transplantation Rates and Outcomes in Severe Leukocyte Adhesion Deficiency Type I (LAD-I): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE609 Return on Investment of National Standardized Health Training in Japan: A Cohort Study Using “Wellness-Star☆” Health Insurance Claims Database

    Dec 1, 2024, 00:00

  • EE330 Healthcare Resource Consumption and Costs of Myasthenia Gravis in France

    Dec 1, 2024, 00:00

  • HPR105 Socioeconomic Indicators of Self-Reported Health Based on EQ-5D-5L: Results From General Population Surveys in England and Spain

    Dec 1, 2024, 00:00

  • EPH99 Sepsis Burden in Europe’s Largest Countries: Hospital-Acquired Cases and Late Diagnosis Impact

    Dec 1, 2024, 00:00

  • HTA120 Interpreting the Non-Inferiority Evidence in NICE Streamlined Cost-Comparison Appraisals

    Dec 1, 2024, 00:00

  • EE322 Understanding Real-World Trends in High Costs, Comorbidities, and Mortality: A Percentile-Based Cohort Comparison in Severe Obesity

    Dec 1, 2024, 00:00

  • EPH228 Trends in Hospital Cases of Clostridioides Difficile Infection in Germany

    Dec 1, 2024, 00:00

  • EPH122 Understanding the Patient Journey of Lung Cancer Patients in China: A Multi-Center Study

    Dec 1, 2024, 00:00

  • EE625 Cost-Effectiveness Analysis of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) to Prevent Pneumococcal Disease in the Greek Pediatric Population

    Dec 1, 2024, 00:00

  • EE627 Hospitalization Costs and Disease Burden ofB. Pertussis in Germany: A Retrospective Analysis of Nationwide Inpatient Data Collected From 2019 to 2023

    Dec 1, 2024, 00:00

  • HTA135 Isatuximab for the Third-Line Treatment of Relapsing or Refractory Multiple Myeloma: Therapeutic Value Classification in Colombia

    Dec 1, 2024, 00:00

  • EPH268 A Population-Based Observational Study of Private Market Uptake of Varicella Vaccination in Denmark

    Dec 1, 2024, 00:00

  • EE696 Decision Model to Evaluate the Cost of Clinical Events Associated With Switching From Apixaban to Rivaroxaban Among Patients With Non-Valvular Atrial Fibrillation in Greece

    Dec 1, 2024, 00:00

  • EPH13 Identifying and Characterizing Pathways to Clinical Diagnosis of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Hospitals in England

    Dec 1, 2024, 00:00

  • HTA180 Linking Clinical Added Value to Normalized Delta QALY: Insights From Therapeutic Product Analysis

    Dec 1, 2024, 00:00

  • PT38 Is There an Increased Risk of Developing Hypertension After a COVID-19 Infection?

    Dec 1, 2024, 00:00

  • HTA146 How Delays in Access Are Losing the Battle Against Cancer: The Impact on Patient and Economic Outcomes

    Dec 1, 2024, 00:00

  • HPR141 The Difference Between Contracted and Actual Drug Purchasing Volumes Under the Volume-Based Procurement Policy: Evidence From Shanghai, China

    Dec 1, 2024, 00:00

  • HPR255 Multi-Stakeholder Recommendations for Action Against Antimicrobial Resistan A Public Consultation

    Dec 1, 2024, 00:00

  • EE425 Cost-Effectiveness Analysis and Budget Impact Model of Lp(A) Testing in Portuguese Patients With Atherosclerotic Cardiovascular Disease for Secondary Prevention

    Dec 1, 2024, 00:00

  • EPH227 Diffuse Large B-Cell Lymphoma in Italy: Treatment Patterns, Survival Outcomes, and Direct Healthcare Costs Through Administrative Healthcare Data

    Dec 1, 2024, 00:00

  • CO47 Candesartan Induced Erectile Dysfunction: Mining and Analysis of Real-World Data Based on US FDA Adverse Event Reporting System Database From 1998 to 2024

    Dec 1, 2024, 00:00

  • HTA67 Tackling Heterogeneity in Indirect Treatment Comparison (ITC): A Comparative Review of NICE Submissions in Oncology Versus Non-Oncology

    Dec 1, 2024, 00:00

  • HSD46 Care Pathway of Lung Cancer and Melanoma Patients Treated With Immune Checkpoint Inhibitors (ICI) in Hospital at Home and Administration Costs in France in 2021 and 2022

    Dec 1, 2024, 00:00

  • EPH193 Associations Between Neutrophil-to-Lymphocyte Ratio and Autoimmune Diseases: Evidence From a Large Prospective Cohort Study

    Dec 1, 2024, 00:00

  • CO119 Methodological Considerations for Time-to-Event Analyses of Non-Interventional Studies (NIS) Collecting Real-World Data (RWD) Prospectively: A Simulation Study

    Dec 1, 2024, 00:00

  • EE387 Model Conceptualization for IDH Mutant Diffuse Glioma: A Case Study Exploring Two Alternative Structures

    Dec 1, 2024, 00:00

  • HPR34 How Payment Schemes Drive the Adoption of Transcatheter Aortic Valve Implantation?

    Dec 1, 2024, 00:00

  • EPH4 The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy

    Dec 1, 2024, 00:00

  • HTA28 Insights on Early Access Refusal in France

    Dec 1, 2024, 00:00

  • EE631 Cost-Effectiveness of Difelikefalin Compared to Best Supportive Care for Treatment of Chronic Kidney Disease-Associated Pruritus in Australia

    Dec 1, 2024, 00:00

  • CO77 Impact of Pharmacist Interventions on Drug Related Problems Among Geriatric Patient's in Tertiary Care Teaching Hospital

    Dec 1, 2024, 00:00

  • HSD67 Current Pharmaceutical Treatment Landscape of Pulmonary Arterial Hypertension (PAH) Patients in Germany: A Claims Data Analysis

    Dec 1, 2024, 00:00

  • EE842 Estimating the Potential Lifetime Health and Economic Impact of V116 on Pneumococcal Disease in Brazil

    Dec 1, 2024, 00:00

  • CO127 Individual Participant Data Meta-Analysis for Time to Event Outcomes: One-Stage or Two-Stage Method?

    Dec 1, 2024, 00:00

  • EE482 The Economic Burden of Smoking in Belgium: Incremental Healthcare and Indirect Costs

    Dec 1, 2024, 00:00

  • EE825 Induction Cost Per Responder of Brodalumab Compared With Other Biologic Therapies for Patients With Moderate to Severe Plaque Psoriasis in Canada

    Dec 1, 2024, 00:00

  • EE644 Budget Impact Analysis of Axitinib (Caxetib®) as Second-Line Therapy for the Treatment of Metastatic Renal Cell Carcinoma in a Cohort in Mexico

    Dec 1, 2024, 00:00

  • P57 Quantifying Inequalities Across the Breast Cancer Pathway and Their Impact on Health Outcomes in England

    Dec 1, 2024, 00:00

  • EE743 Assessment of the Budgetary Impact of Introducing Pegcetacoplan and Ravulizumab for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in the Kingdom of Saudi Arabia

    Dec 1, 2024, 00:00

  • EE481 Direct and Indirect Costs Associated With Generalized Anxiety Disorder Among Adults in the United States

    Dec 1, 2024, 00:00

  • EPH206 Cost of Treatment for Hereditary Angioedema in a Poor Population in Colombia

    Dec 1, 2024, 00:00

  • HTA176 Assessing Trends in European Union’s Health Technology Assessment Submissions of Antibody-Drug Conjugates

    Dec 1, 2024, 00:00

  • HTA8 Changes in NICE Guidance Following Surveillance Review: When, How and Why?

    Dec 1, 2024, 00:00

  • HTA200 Understanding Joint Clinical Assessment Scoping Requirements in Oncology: Results of a Rapid PICO Prediction Exercise Via an In-House Expert Network

    Dec 1, 2024, 00:00

  • EE459 Cost-Effectiveness Analysis of Adjuvant Alectinib Compared to Platinum-Based Adjuvant Chemotherapy in Patients With Resectable ALK-Positive NSCLC in Italy

    Dec 1, 2024, 00:00

  • HPR107 The Devil in the Detail: The Challenges of Evaluating Patient Access to Medicines

    Dec 1, 2024, 00:00

  • EE284 Internal Validation of the Metabo-Reno-Cardiovascular Disease Model: Cardiovascular Outcomes in Type 1 Diabetes

    Dec 1, 2024, 00:00

  • EPH201 Impact of Smoking History on the Real-World Effectiveness of Immune Checkpoint Inhibitors in Previously Treated Non-Small Cell Lung Cancer: A Nationwide Population-Based Study

    Dec 1, 2024, 00:00

  • HSD129 Adherence to NICE Guidelines for Chronic Obstructive Pulmonary Disease Can Improve Patient Outcomes and Reduce Carbon Footprint When Compared With Current Clinical Practice

    Dec 1, 2024, 00:00

  • EPH160 A Targeted Literature Review to Assess the Impact of Environmental and Socio-Demographic Factors on the Onset of Type 1 Diabetes

    Dec 1, 2024, 00:00

  • EE274 An Open Systematic Review on Methodology and Quality of Economic Evaluations of Breast Cancer Screening Strategies

    Dec 1, 2024, 00:00

  • EE238 Budget Impact and the Cost-Effectiveness of Introducing Voretigene Neparvovec for Treating Inherited Retinal Diseases in the Kingdom of Saudi Arabia

    Dec 1, 2024, 00:00

  • HTA55 A Targeted Review of the Challenges and Strategies for Submitting Patient-Generated Evidence to Health Technology Assessment (HTA) Agencies

    Dec 1, 2024, 00:00

  • HTA43 Comparative Environmental Impact Assessment of Intravenuous and Subcutanuous Daratumumab Administration in Italy: An Applied Case Study

    Dec 1, 2024, 00:00

  • EE531 Evaluation of the Cost-Effectiveness of a Nationwide Precision Medicine Program for Patients With Advanced Non-Small Cell Lung Cancer in Germany

    Dec 1, 2024, 00:00

  • EPH166 Trends in Epidemiology and Mortality of Patients With Breast Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HSD59 Addressing Postnatal Depression: Disparities in Treatment Availability

    Dec 1, 2024, 00:00

  • EE371 Cost-Effectiveness of the Absorbable Antibacterial Envelope for Infection Control in Cardiac Implantable Electronic Device Implantation in Spain

    Dec 1, 2024, 00:00

  • CO9 Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

    Dec 1, 2024, 00:00

  • EE424 The Cost-Effectiveness of Adding Uwhangchungsimwon to Donepezil With Respect to Mild Alzheimer's Behavioral and Psychological Symptoms in Korea: A Decision-Tree Model Based on Clinical Trial

    Dec 1, 2024, 00:00

  • EE344 Updated Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Therapy for Renal Cell Carcinoma After Nephrectomy in the United States

    Dec 1, 2024, 00:00
  • 1
  • 2
  • 3 (current)
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »